Johnson & Johnson

VN:F [1.9.11_1134]
Rating: 0 (from 0 votes)
Last year, Johnson & Johnson CEO Bill Weldon called 2009 one of the most challenging years in the company’s history. 2010 hasn’t been any easier.J&J has had to deal with 11 major FDA recalls in the past year, including a recent recall of leaky insulin cartridges. The company faces strict regulatory oversight at its McNeil plants the next five years under an agreement with the FDA. Regulators abroad are taking actions too: J&J’s Acuvue and TruEye contact lenses were recalled in Europe and Asia last August due to manufacturing problems. Weldon insists that the company’s problems are being addressed. —S.D.

source

Pfizer

VN:F [1.9.11_1134]
Rating: 0 (from 0 votes)
An expiring patent for the little blue pill is making Pfizer blue these days. Pfizer’s blockbuster Viagra will face competition from generics starting next year. To prepare, the company is scrambling to find other uses for the drug. It’s also making variations of Viagra, such as a chewable tablet called Viagra Jet, which it’s already selling in Mexico.Like many big pharmas facing a generics threat, Pfizer is slimming down and restructuring. It recently closed its major research facility in Sandwich, England, which employed 2,400 people. In March, Pfizer also announced a strategy to spin off four non-pharma units to focus on its core business. —S.D.

source